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Ciprofloxacin decreases the clearance of antipyrine and other drugs which, in part,
undergo oxidative metabolism. Based on these findings, the authors hypothesized that
ciprofloxacin may decrease the clearance of quinidine, a drug which also undergoes
oxidative metabolism. The purpose of this study was to evaluate the effect of ciprofloxa-
cm on the pharmacokinetic and ECG parameters of quinidmne in seven healthy men.
Oral quinidine sulfate 400 mg was administered alone (Phase A) and after oral cipro-
floxacin pretreatment (Phase B) in a randomized crossover fashion with a 2-week wash-
out period between each phase. During Phase B, ciprofloxacin pretreatment (750 mg
every 12 hours) was administered for 5 days before and 24 hours after quinidine adminis-
tration. Quinidine serum samples were obtained over a 24-hour period. QBS and QTc
intervals were measured over a 12-hour period. There were no significant differences in
clearance (20.3 ± 3.3 L/hr vs 20.1 ± 2.3 L/hr, P = .836), half-life (7.9 ± 1 hr vs 7.8 ± 0.8 hr.
P = 0.8), maximum concentration (1.4 ± 0.6 mg/L vs 1.5 ± 0.6 mg/L, P = 0.613), or time to
maximum concentration (1.5 ± 0.2 hr vs 1.5 ± 0.1 hr, P = 0.571) for quinidine between
Phase A and Phase B, respectively. The largest decrease in clearance observed for Phase
B compared to Phase A was 10%. There was also no significant difference in the degree of
QRS and QTc prolongation between Phase A and Phase B. From these results, itappears
that ciprofloxacin in the dose given does not alter the pharmacokinetic or ECG parame-
ters of qumnidmne. Therefore, no adjustment in the dose of quinidine is needed when
coadministered with ciprofloxacin.
C iprofloxacin is an orally available fluoroquino-
lone antibiotic with a broad spectrum of gram-
positive and gram-negative activity. It is used for the
treatment of a wide variety of infections, including
pneumonia, skin and soft tissue, urinary tract, and
other serious infections. Ciprofloxacin is eliminated
in part by oxidative pathways; the M3 metabolite of
ciprofloxacin comprises approximately 9.6% of the
urinary excretion of ciprofloxacin following an oral
dose of 250 mg in healthy volunteers.1 Therefore, it
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is not surprising that ciprofloxacin has been shown
to decrease the metabolic clearance of caffeine, the-
ophylline, and antipyrine, which also undergo he-
patic oxidation.2-6
Because ciprofloxacin is widely used in both the
community and hospital settings, there is a potential
for concurrent administration with other drugs that
are eliminated by oxidative pathways such as caf-
feine or theophylline. Quinidine also undergoes ox-
idative metabolism, and its clearance is affected by
inhibitors of oxidative metabolism such as cimeti-
dine, propranolol, and verapamil.7 Like ciprofiox-
acm, these agents also decrease the clearance of an-
tipyrine.124 Therefore, it is likely that ciprofloxacin
will also decrease the clearance of quinidine. Since
ciprofloxacin and quinidine are widely used, con-
comitant administration of both agents is likely to
occur.
Quinidine is an antiarrhythmic agent with a nar-
row therapeutic range; serum concentrations are
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usually maintained between 2 and 5 mg/L for the
control of atrial and ventricular arrhythmias. The
narrow therapeutic range of quinidine suggests that
any reduction in the clearance of quinidmne is likely
to be of pharmacokinetic and pharmacodynamic sig-
nificance. Therefore, the purpose of this study was
to determine the effect of ciprofloxacin coadminis-
tration on the pharmacokinetic and ECG parameters
of quinidine.
METHODS
Eight healthy nonsmoking male subjects between
the ages of 22 and 34 years were enrolled in the
study. Each subject was considered healthy based
upon history, physical examination, ECG, blood
chemistry, and hematological screen. All subjects
were within 20% of ideal body weight. Subjects
were asked to refrain from taking any drugs (includ-
ing over-the-counter products), or xanthine-con-
taming foods (including caffeine) 48 hours before
each phase of the study. Subjects who had taken any
drugs known to induce liver enzymes within the
past 30 days were excluded from the study. The
study was approved by The University of Michigan
Institutional Review Board and written informed
consent was obtained from all subjects. The study
was performed in the Clinical Research Center.
The study consisted of two phases with a 2-week
washout period between phases. In a randomized
crossover design, subjects received a 400 mg oral
dose of quinidine sulfate (Warner Chilcott, Morris
Plains, NJ) alone or after pretreatment with oral ci-
profioxacin (Miles Inc., West Haven, CT) 750 mg at
7:00 AM and 7:00 PM for 5 days. Quinidine was ad-
ministered with 240 mL of water after an overnight
fast and blood samples were obtained from an in-
dwelling venous catheter in an antecubital vein at 0
(predose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0,
12.0, and 24.0 hours after administration of quini-
dine. During the treatment phase of the study, ci-
profioxacin was administered 30 minutes before the
quinidine dose after an overnight fast. Ciprofioxacin
was administered throughout the 24-hour quinidine
sampling period as previously scheduled. During the
first 12 hours of serum sampling, single lead electro-
cardiogram monitoring was performed with a car-
diac monitor (Mennem Medical 741, Clarence NY)
after each blood sample was obtained. Subjects were
provided a standard meal after the 4.0 and 8.0 hour
blood samples. Blood samples were drawn into un-
heparinized vacuum tubes (Becton Dickinson,
Rutherford NJ) and allowed to clot. After centrifuga-
tion the serum was harvested and stored at -20#{176}C
pending analysis.
Drug Analysis
Quinidine serum concentrations were determined
by a fluorescence polarization method (TDx, Abbott
Laboratories, North Chicago, IL). This method has
been reported to be specific for quinidine.’5 The
coefficient of variation was less than 5% over the
concentration range of 0.05 to 2.0 mg/L. The serum
free fraction of quinidine was determined by ultra-
filtration (Amicon Centrifree Micropartition System,
Amicon Corp., Danvers, MA) of the serum samples
obtained at 2.0 hours after administration of quini-
dine. The pH of the ultrafiltrate was adjusted to a
physiological pH of approximately 7.40 with IM
phosphoric acid prior to analysis.16”7 Ciprofloxacin
serum concentrations were determined by a micro-
biological assay employing Bacillus subtilis ATCC
6633 as the test organism.
Data Analysis
The apparent oral clearance of quinidine was calcu-
lated by dividing the administered dose in terms of
quinidine base by the area under the serum concen-
tration-time curve from zero to infinity (AUC). The
AUC was calculated using the linear trapezoidal
method. The elimination half-life (ti/2) was deter-
mined by linear regression analysis of the terminal
phase of the log concentration-time profile. The
mean maximal serum concentration (Gmax) and time
to Cmax (tmax) was determined by visual inspection of
the available data points.
The QRS and QTc intervals were measured by a
trained nurse who was blinded to the study. The
QRS and QTc intervals were determined over a 10-
beat interval and are reported as average values. The
QTc interval was calculated by dividing the QT in-
terval by the square root of the R-R interval. The
variability in measuring the EGG intervals was eval-
uated by determining the mean percentage of dif-
ference from repeated measurements of a random
sampling of EGG parameters. The intraperson per-
cent difference was less than 6% for all EGG parame-
ters measured. A random sample of EGG parameters
were also measured by a second trained person who
was also blinded; the interperson mean percent dif-
ference for the EGG parameters measured was less
than 8%. The area under the electrocardiographic
parameter percent change versus time curve (AUC-
E) was determined for each subject from 0-12 hours
using the linear trapezoidal method.9
Statistical comparison between the two phases
was performed using a two-tailed paired Student’s
test. A P value of less than .05 was considered statis-
-0- Qulnldlne
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Figure 1. Quinidine serum concentration versus time curve for
quinidine and quinidine plus ciprofloxacin phases. (Mean and
standard deviation).
tically significant. The reported data are represented
as the mean and standard deviation unless other-
wise specified.
RESULTS
Seven of the eight patients completed both phases of
the study. One patient withdrew from the study sec-
ondary to development of a rash after ciprofloxacin
administration. All subjects were compliant with
the ciprofloxacin regimen as assessed by patient
questioning.
The mean serum quinidine concentration versus
time profile for each phase is presented in Figure 1.
The pharmacokinetic data for each subject are sum-
marized in the Table. Quinidine clearance was not
significantly altered after ciprofloxacin administra-
tion, 20.3 ± 3.3 L/hr vs 20.1 ± 2.3 L/hr (P = .836) for
the control (quinidine alone) and treatment phases
(quinidine and ciprofloxacin) respectively. The
maximal percent decrease in clearance from the
control phase to treatment phase was 10%, with a
mean decrease of 8.5 ± 2.0% in four out of the seven
patients demonstrating a decrease in quinidine
clearance. Overall, there was less than a 1% de-
crease in quinidine clearance between the control
and treatment phases. There was no statistical dif-
ference in the half-life between the two phases (P
= .8).
There was no statistical difference in Cmax, tmax, or
free fraction of quinidine between control and treat-
ment phases. The Cmax values during control and
treatment phases were 1.4 ± 0.6 mg/L and 1.5 ± 0.6
mg/L (P = .613), respectively and tmax values were
1.5 ± 0.2 hours vs 1.5 ± 0.1 hours (P = .571) for the
control and treatment phases, respectively. The free
fraction of quinidine was similar between the con-
trol and treatment phase, 21 ± 5.5% vs. 20 ± 3.5%,
respectively.
The percentage of change from baseline in the
QRS and QTc interval during each time period mea-
sured is shown in Figures 2 and 3. The AUG-E for the
QRS and QTc interval was not significantly different
between the control and treatment phases. The
maximal percent increase in the QRS interval from
baseline occurred at 2.0 hours for the control and
treatment phase, 12.1 ± 4% vs. 10.7 ± 6.7%, respec-
tively (mean and standard error). The maximal per-
cent increase in the QTc interval from baseline oc-
curred at 1.5 hours for the control and treatment
phase, 17 ± 3.1% vs. 15 ± 2.8%, respectively (mean
and standard error).
The concentration of ciprofloxacin in serum 2
hours after dosing with quinidine averaged 2.83
± 0.12 mg/L.
DISCUSSION
The current study evaluated the influence of cipro-
floxacin on the pharmacokinetic and EGG parame-
ters of quinidine. The pharmacokinetic parameters
of quinidine during the control phase and the cipro-
floxacin serum concentration observed during the
treatment phase of this study was consistent with
previous reports in the literature.911’1819 In this study
the oral clearance, t112, and tmax were not al-
tered by ciprofloxacin administration. The mean
decrease in quinidine clearance was less than 1%
and no subject experienced a greater than 10% de-
crease in quinidine clearance during the treatment
TABLE
Quinidine Pharmacokinetic Parameters Before and
After Ciprofloxacin Administration
Oral Clea rance (L/hr) t (hr)
Qulnldlne Qulnidlne
Subject Qulnldlne + Ciprofloxacln Qulnldlne + Clprofloxacln
1 19.9 18.0 8.2 8.2
2 20.1 20.8 7.8 8.3
3 20.4 19.2 9 8.2
4 23.8 21.8 7.1 6.5
5 23.8 21.4 8 8.3
6 20.2 23.0 6.1 6.7
7 13.6 16.3 9 8.4
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Figure 2. Percentage of change in the QRS interval from baseline
over a 12-hour time period for quinidine and quinidine plus cipro-
floxacin phases. (Mean and standard error).
phase compared to the control phase. In both phases
the QRS and QTc interval increased during the
study period, consistent with quinidine’s electro-
physiological properties. In agreement with the
pharmacokinetic findings, there was no obvious dif-
ference in the degree of QRS or QTc prolongation
between the treatment and control phases.
Based on recent studies with theophylline, caf-
feine, and antipyrine suggesting that ciprofloxacin
may interfere with oxidative metabolism, it was ex-
pected that ciprofloxacin would decrease the clear-
ance of quinidine.26 Surprisingly, the results of the
study demonstrated that ciprofloxacin had no effect
on the clearance of quinidine. From these results it
is clear that the effect of ciprofloxacin on antipyrine
or theophylline clearance cannot always be extrapo-
lated to other drugs.2#{176}Giprofloxacin may inhibit spe-
cific oxidative pathways responsible for antipyrine,
theophylline, or caffeine metabolism. Therefore,
substrate specificity for different forms of cy-
tochrome P-450 by ciprofloxacin may account for
the drug interactions that are observed with anti-
pyrine, theophylline, and caffeine but not for quini-
dine.
Although, the specific isoenzymes inhibited by
ciprofloxacin are not known, some generalizations
can be made. Quinidine is metabolized apparently
in part by the cytochrome P-450NF isoenzyme.2’
Since quinidine clearance was not affected by ci-
profloxacin administration it can be postulated that
ciprofloxacin does not interfere with the metabolism
of drugs which undergo metabolism by the cy-
tochrome P-450NF isoenzyme and which have a sim-
ilar affinity for the isoenzyme as quinidine. In sup-
port of this a recent study showed that the synthesis
of testosterone, which is affected by the P-450NF
isoenzyme, was not inhibited by ciprofloxacin ad-
ministration.22 In contrast, ciprofloxacin does appear
to inhibit the isoenzymes responsible for the metab-
olism of theophylline, caffeine, and antipyrine.
However, it is unknown which specific isoenzymes
and metabolic pathways of these drugs are inhibited
by ciprofloxacin. Further studies with in vitro
models involving specific human isoenzymes are
necessary to determine the relationship between ci-
profloxacin and drug metabolism.
Other possible reasons for a negative study in-
clude dose and duration of drug therapy or Type II
error. Ciprofloxacin was administered over a 6-day
period at a dose of 750 mg twice a day. The time
period over which ciprofloxacin was administered
would allow for achievement of steady state levels of
ciprofloxacin and is in agreement with the time pe-
riods used in other studies evaluating interactions
with antipyrine and theophylline.25 The dose eval-
uated is the maximum recommended dose and if a
drug interaction is to occur it should be apparent at
this dose. Therefore, it is unlikely that the dose or
duration of ciprofloxacin therapy used in this study
would result in a negative study. A clinically signifi-
cant Type II error is also unlikely to account for a
negative study. This study should be able to detect
an 18% change in quinidine clearance based on a
power value of 0.8 and seven subjects. Any change
in clearance less than 18% and particularly under
Figure 3. Percentage of change in the QTc interval from baseline
over a 12-hour time period for quinidine and quinidine plus cipro-
floxacin phases. (Mean and standard error).
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10% is unlikely to be clinically relevant. Assuming
linear pharmacokinetics for quinidine, a 10%
change in the clearance of quinidine would result in
an increase in average quinidine steady state serum
concentrations of less than 11%, which would not
necessitate a dosage adjustment. No subject in this
study demonstrated a change in quinidine clearance
greater than 10% in the treatment phase as com-
pared to the control phase.
What is not known from this study is the effect of
other quinolone antibiotics on quinidine metabo-
lism and clearance. Other quinolone antibiotics,
particularly enoxacin which is extensively metabo-
lized to a 4-oxo-quinolone metabolite may interfere
with quinidine metabolism. The 4-oxo-quinolone
metabolite has been postulated to be responsible for
the inhibition of theophylline metabolism.2 How-
ever, the role of the 4-oxo-quinolone metabolite in
interfering with drug metabolism is controver-
sial.4’6’23 Additional studies are required to address
this issue.
In conclusion, the results of this study showed
that ciprofloxacin does not alter the pharmacoki-
netic or electrocardiographic parameters of quini-
dine. No dosage adjustments are required for quini-
dine when administered with ciprofloxacin. Pre-
vious studies demonstrating drug interactions with
antipyrine and theophylline were not predictive
with quinidine. Additional studies are required to
determine if other quinolone antibiotics may cause
significant drug interaction with quinidine.
The authors are grateful to Debbie Loughry for her secretarial
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